Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research
C
Diagnostics & Research is Zen Rated C and is the 82nd ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
FONR
FONAR CORP
$102.15MN/A0.00%N/AN/AN/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$7.49BN/A0.00%N/AN/AN/AN/A
SHC
SOTERA HEALTH CO
$4.61BN/A0.00%N/AN/AN/AN/A
IDXX
IDEXX LABORATORIES INC
$51.52BN/A0.00%N/AN/AN/AN/A
QGEN
QIAGEN NV
$9.88BN/A0.00%$1.2800N/AN/A0
EXAS
EXACT SCIENCES CORP
$10.12BN/A0.00%N/AN/AN/AN/A
DHR
DANAHER CORP
$135.00B0.48%24.90%$0.3200$0.919%22025-09-262025-10-31
LH
LABCORP HOLDINGS INC
$22.89B1.05%31.50%$0.7200$2.8824%0
A
AGILENT TECHNOLOGIES INC
$35.62B0.58%22.90%$0.2480$0.7312%0
WAT
WATERS CORP
$17.80BN/A0.00%N/AN/AN/AN/A
ILMN
ILLUMINA INC
$15.51BN/A0.00%N/AN/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$25.96BN/A0.00%N/AN/AN/AN/A
TMO
THERMO FISHER SCIENTIFIC INC
$179.16B0.26%9.50%$0.4300$1.254%02025-10-15
MEDP
MEDPACE HOLDINGS INC
$13.95BN/A0.00%N/AN/AN/AN/A
XGN
EXAGEN INC
$204.85MN/A0.00%N/AN/AN/AN/A
DGX
QUEST DIAGNOSTICS INC
$20.20B1.30%36.60%$0.8000$2.3531%02025-10-032025-10-20
FLGT
FULGENT GENETICS INC
$672.79MN/A0.00%N/AN/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$1.55BN/A0.00%N/AN/AN/AN/A
IQV
IQVIA HOLDINGS INC
$31.61BN/A0.00%N/AN/AN/AN/A
RVTY
REVVITY INC
$9.75B0.25%11.90%$0.0700$0.213%02025-10-172025-11-07
MYGN
MYRIAD GENETICS INC
$680.16MN/A0.00%N/AN/AN/AN/A
RDNT
RADNET INC
$5.77BN/A0.00%N/AN/AN/AN/A
NEO
NEOGENOMICS INC
$1.04BN/A0.00%N/AN/AN/AN/A
PRE
PRENETICS GLOBAL LTD
$129.56MN/A0.00%N/AN/AN/AN/A
ACRS
ACLARIS THERAPEUTICS INC
$199.24MN/A0.00%N/AN/AN/AN/A
MDXH
MDXHEALTH SA
$18.12MN/A0.00%N/AN/AN/AN/A
NTRA
NATERA INC
$23.51BN/A0.00%N/AN/AN/AN/A
GH
GUARDANT HEALTH INC
$6.83BN/A0.00%N/AN/AN/AN/A
GRAL
GRAIL INC
$1.42BN/A0.00%N/AN/AN/AN/A
CSTL
CASTLE BIOSCIENCES INC
$627.16MN/A0.00%N/AN/AN/AN/A
ICLR
ICON PLC
$13.26BN/A0.00%N/AN/AN/AN/A
LAB
STANDARD BIOTOOLS INC
$523.33MN/A0.00%N/AN/AN/AN/A
STIM
NEURONETICS INC
$189.78MN/A0.00%N/AN/AN/AN/A
CAI
CARIS LIFE SCIENCES INC
$9.31BN/AN/AN/AN/AN/AN/A
NOTV
INOTIV INC
$47.06MN/A0.00%N/AN/AN/AN/A
PSNL
PERSONALIS INC
$525.85MN/A0.00%N/AN/AN/AN/A
SERA
SERA PROGNOSTICS INC
$117.99MN/A0.00%N/AN/AN/AN/A
CDNA
CAREDX INC
$746.24MN/A0.00%N/AN/AN/AN/A
ISPC
ISPECIMEN INC
$9.47MN/A0.00%N/AN/AN/AN/A
NEOG
NEOGEN CORP
$1.19BN/A0.00%N/AN/AN/AN/A
BDSX
BIODESIX INC
$55.72MN/A0.00%N/AN/AN/AN/A
OPK
OPKO HEALTH INC
$1.10BN/A0.00%N/AN/AN/AN/A
APDN
APPLIED DNA SCIENCES INC
$3.59MN/A0.00%N/AN/AN/AN/A
PRPO
PRECIPIO INC
$30.32MN/A0.00%N/AN/AN/AN/A
XWEL
XWELL INC
$6.22MN/A0.00%N/AN/AN/AN/A
BNR
BURNING ROCK BIOTECH LTD
$93.79MN/A0.00%N/AN/AN/AN/A
ADVB
ADVANCED BIOMED INC
$11.25MN/AN/AN/AN/AN/AN/A
DRIO
DARIOHEALTH CORP
$15.17MN/A0.00%N/AN/AN/AN/A
MYNZ
MAINZ BIOMED NV
$3.65MN/A0.00%N/AN/AN/AN/A
PRPH
PROPHASE LABS INC
$17.86MN/A0.00%$0.3000N/AN/A0
NDRA
ENDRA LIFE SCIENCES INC
$3.67MN/A0.00%N/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$21.37MN/A0.00%N/AN/AN/AN/A
CHEK
CHECK-CAP LTD
$12.40MN/A0.00%N/AN/AN/AN/A
VNRX
VOLITIONRX LTD
$67.79MN/A0.00%N/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$9.96MN/A0.00%N/AN/AN/AN/A
IMDX
INSIGHT MOLECULAR DIAGNOSTICS INC
$88.44MN/A0.00%N/AN/AN/AN/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Sep 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 13 points higher than the diagnostic & research industry average of 26.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -9.72% over the past year, overperforming other diagnostic & research stocks by 11 percentage points.

2. Charles River Laboratories International (NYSE:CRL)


Charles River Laboratories International (NYSE:CRL) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Charles River Laboratories International (NYSE:CRL) is: Value: C, Growth: B, Momentum: D, Sentiment: A, Safety: B, Financials: B, and AI: B.

Charles River Laboratories International (NYSE:CRL) has a Due Diligence Score of 14, which is -12 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates CRL as a "A".

CRL passed 4 out of 33 due diligence checks and has weak fundamentals. Charles River Laboratories International has seen its stock lose -25.27% over the past year, underperforming other diagnostic & research stocks by -5 percentage points.

Charles River Laboratories International has an average 1 year price target of $173.00, an upside of 13.64% from Charles River Laboratories International's current stock price of $152.24.

Charles River Laboratories International stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Charles River Laboratories International, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 55.56% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: A, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 20, which is -6 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 7 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock lose -4.02% over the past year, overperforming other diagnostic & research stocks by 17 percentage points.

Sotera Health Co has an average 1 year price target of $14.33, a downside of -11.69% from Sotera Health Co's current stock price of $16.23.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Sotera Health Co, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.3%, which is 1 percentage points higher than the diagnostic & research industry average of 0.65%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.6% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.05%, which is the same as the diagnostic & research industry average of 0.65%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 31.5% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.58%, which is the same as the diagnostic & research industry average of 0.65%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.18% in the last day, and down -2.23% over the last week. Check Cap was the among the top gainers in the diagnostics & research industry, gaining 184.18% yesterday.

Check-Cap shares are trading higher after the company and MBody AI announced a definitive merger agreement.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 28 points higher than the diagnostic & research industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has dropped -42.33% in the past year. It has underperformed other stocks in the diagnostic & research industry by -22 percentage points.

2. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 56 points higher than the diagnostic & research industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -9.72% in the past year. It has overperformed other stocks in the diagnostic & research industry by 11 percentage points.

3. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -2.53% in the past year. It has overperformed other stocks in the diagnostic & research industry by 18 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 10.06% over the next year.

6.98% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 11.63% of diagnostic & research stocks are rated B (Buy), 62.79% are rated C (Hold), 13.95% are rated D (Sell), and 4.65% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 20.57x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.